These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38124038)

  • 1. The value of serum neutralizing antibody in evaluating predictability of COVID-19 after recovery and the validation of vaccine.
    Guo B; Li Z; Fu G; Li H; Yang J; Zhang Z; Wu L; Wang J
    BMC Infect Dis; 2023 Dec; 23(1):895. PubMed ID: 38124038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test.
    Kitagawa Y; Imai K; Matsuoka M; Fukada A; Kubota K; Sato M; Takada T; Noguchi S; Tarumoto N; Maesaki S; Takeuchi S; Maeda T
    J Med Virol; 2022 Jan; 94(1):335-341. PubMed ID: 34524695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic Value of a SARS-CoV-2 Rapid Test Kit for Detection of Neutralizing Antibodies as a Point-of-Care Surveillance Test.
    Chan MMH; Leung KY; Zhang RRQ; Liu D; Fan Y; Khong MKW; Tam AR; Chen H; Yuen KY; Hung IFN; Chan KH
    Microbiol Spectr; 2022 Apr; 10(2):e0099321. PubMed ID: 35254121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of SARS-CoV-2 Neutralizing Antibodies to an Automated Chemiluminescent Serological Immunoassay.
    Grenache DG; Ye C; Bradfute SB
    J Appl Lab Med; 2021 Mar; 6(2):491-495. PubMed ID: 33098417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response.
    Takamatsu Y; Omata K; Shimizu Y; Kinoshita-Iwamoto N; Terada M; Suzuki T; Morioka S; Uemura Y; Ohmagari N; Maeda K; Mitsuya H
    Microbiol Spectr; 2022 Dec; 10(6):e0271622. PubMed ID: 36219096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulins using chemiluminescence immunoassay and its correlation with neutralizing antibodies.
    Gaber Y; Abdel Alem S; Musa S; Amer K; Elnagdy T; Hassan WA; Abdelrahman RZ; Gad A; Ali MA; Badary HA; Shawky S; Talaat H; Kassem AM; Fouad R
    Virus Res; 2022 Oct; 319():198852. PubMed ID: 35834979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients.
    Chansaenroj J; Yorsaeng R; Puenpa J; Wanlapakorn N; Chirathaworn C; Sudhinaraset N; Sripramote M; Chalongviriyalert P; Jirajariyavej S; Kiatpanabhikul P; Saiyarin J; Soudon C; Thienfaidee O; Ayuthaya TPN; Brukesawan C; Intharasongkroh D; Chaiwanichsiri D; Issarasongkhram M; Kitphati R; Mungaomklang A; Thitithanyanont A; Nagavajara P; Poovorawan Y
    PLoS One; 2022; 17(4):e0267102. PubMed ID: 35446889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic observation of SARS-CoV-2 IgM, IgG, and neutralizing antibodies in the development of population immunity through COVID-19 vaccination.
    Jiang R; Dou X; Li M; Wang E; Hu J; Xiong D; Zhang X
    J Clin Lab Anal; 2022 Apr; 36(4):e24325. PubMed ID: 35235705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Shedding of SARS-CoV-2 Virus in COVID-19 Patients and Neutralizing Antibody Level].
    Ayhancı T; Toptan H; Özer YE; Uzar S; Enül H; Adıay C; Sarac F; Dheir H; Köroğlu M; Hasöksüz M; Altındiş M
    Mikrobiyol Bul; 2022 Jul; 56(3):416-431. PubMed ID: 35960235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.
    Wang K; Long QX; Deng HJ; Hu J; Gao QZ; Zhang GJ; He CL; Huang LY; Hu JL; Chen J; Tang N; Huang AL
    Clin Infect Dis; 2021 Aug; 73(3):e531-e539. PubMed ID: 32745196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal profile of neutralizing and binding antibodies in vaccinated and convalescent COVID-19 cohorts by chemiluminescent immunoassays.
    Dou X; Wang E; Jiang R; Li M; Xiong D; Sun B; Zhang X
    Immun Inflamm Dis; 2022 Jun; 10(6):e612. PubMed ID: 35634960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies.
    Solastie A; Virta C; Haveri A; Ekström N; Kantele A; Miettinen S; Lempainen J; Jalkanen P; Kakkola L; Dub T; Julkunen I; Melin M
    Microbiol Spectr; 2021 Dec; 9(3):e0113121. PubMed ID: 34787485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between SARS-COV-2 antibody screening by immunoassay and neutralizing antibody testing.
    Mendrone-Junior A; Dinardo CL; Ferreira SC; Nishya A; Salles NA; de Almeida Neto C; Hamasaki DT; Facincani T; de Oliveira Alves LB; Machado RRG; Araujo DB; Durigon EL; Rocha V; Sabino EC
    Transfusion; 2021 Apr; 61(4):1181-1190. PubMed ID: 33491194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 Infection.
    Tyner HL; Burgess JL; Grant L; Gaglani M; Kuntz JL; Naleway AL; Thornburg NJ; Caban-Martinez AJ; Yoon SK; Herring MK; Beitel SC; Blanton L; Nikolich-Zugich J; Thiese MS; Pleasants JF; Fowlkes AL; Lutrick K; Dunnigan K; Yoo YM; Rose S; Groom H; Meece J; Wesley MG; Schaefer-Solle N; Louzado-Feliciano P; Edwards LJ; Olsho LEW; Thompson MG
    Clin Infect Dis; 2022 Aug; 75(1):e827-e837. PubMed ID: 34928334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric population (aged 3-11 years) received primary inactivated SARS-CoV-2 vaccination prior to infection exhibiting robust humoral immune response following infected with Omicron variant: a study conducted in Beijing.
    Li J; Li J; Dai S; Dang L; Wang L; Cao L; Chen X; Wang Y; Ge M; Liu W; Song Q; Xu W; Ma L
    Front Immunol; 2023; 14():1269665. PubMed ID: 37828994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2.
    Nickel O; Rockstroh A; Wolf J; Landgraf S; Kalbitz S; Kellner N; Borte M; Pietsch C; Fertey J; Lübbert C; Ulbert S; Borte S
    PLoS One; 2022; 17(10):e0263861. PubMed ID: 36256664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The instantly blocking-based fluorescent immunochromatographic assay for the detection of SARS-CoV-2 neutralizing antibody.
    Li Y; He J; Zhang Y; Liang D; Zhang J; Ji R; Wu Y; Su Z; Ke C; Xu N; Tang Y; Xu J
    Front Cell Infect Microbiol; 2023; 13():1203625. PubMed ID: 37736103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China.
    Wu F; Liu M; Wang A; Lu L; Wang Q; Gu C; Chen J; Wu Y; Xia S; Ling Y; Zhang Y; Xun J; Zhang R; Xie Y; Jiang S; Zhu T; Lu H; Wen Y; Huang J
    JAMA Intern Med; 2020 Oct; 180(10):1356-1362. PubMed ID: 32808970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.